IDYA250117C40000
- 5.00
- 0.000.00%
IDEAYA Biosciences Newsroom
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $55
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and IDEAYA Biosciences (IDYA)
IDEAYA Biosciences (IDYA) Receives a Hold From Leerink Partners
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
IDEAYA Biosciences Analyst Ratings
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
IDEAYA Biosciences: Promising Pipeline and Strong Financials Make for a Buy Recommendation
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Stephens Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51
IDEAYA Biosciences Analyst Ratings
Ideaya Biosciences Initiated With an Overweight at Stephens
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
IDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy Rating
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $64
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61